Video

CancerTYPE ID and Next-Generation Sequencing

CancerTYPE ID (CTID) can help determine the tissue of origin and help to determine a tumor subtype, in conjunction with clinical and pathological assessments. Additionally, a prospective study of 444 patients, examined the utilization of CTID as a decision-making aid, notes F. Anthony Greco, MD.

In the study, results from CTID altered the treatment decision for 46% of patients, notes Greco. Some of these patients received additional molecular testing because of their diagnosis, to determine the presence of actionable mutations that could be treated with targeted therapy, particularly in adenocarcinoma of the lung, colon, and breast.

Another study evaluated the bioT3 program, which is a combination of the CTID molecular classifier and next generation sequencing plus (NGS+) with selected fluorescence in situ hybridization (FISH) and immunohistochemical (IHC) staining, says Greco. This study assessed 465 patients with unclear or unknown primary cancer, with 27 distinct tumor types detected.

Of the tumor types identified, the test uncovered 70 patients (15%) with non-small cell lung cancer. Of these patients, 51% harbored actionable molecular abnormalities determined by the NGS+ portion of the bioT3 platform. These abnormalities included KRAS (25.7%), KIT (21.4%), EGFR (8.6%), PIK3CA (7.1%), and BRAF (2.9%).

Related Videos
Dr Jabbour on Bleximenib Monotherapy in KMT2A+ or NPM1+ R/R Acute Leukemia
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
Alexander I. Spira MD, PhD, FACP, FASCO
In this episode of OncChats: A Close Look at Clinical Trials in Oncology and Beyond, Dr Carvajal discusses the progress made in cancer clinical trials, with nearly 20,000 trials worldwide and over 80 FDA-approved cancer drugs since 2015, while also noting the challenges posed by the increasing complexity of therapies and trial protocols.